5-(2-Methylpropanoyl)pyrrolidin-2-one | 1783350-08-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 5-(2-Methylpropanoyl)pyrrolidin-2-one
• CAS: 1783350-08-2
• 化学式: C₈H₁₃NO₂
• 分子量: 155.19
• InChiKey: RFVFIDVLYBMKMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：ENANTA PHARM INC

  公开号：WO2010099527A1

  公开（公告）日：2010-09-02

  The present invention discloses compounds or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了抑制RNA含病毒，特别是丙型肝炎病毒（HCV）的化合物或药用可接受的盐、酯或前药，因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
• Quinazoline derivatives
  申请人：Hennequin Francois Andre Laurent

  公开号：US20070032513A1

  公开（公告）日：2007-02-08

  The invention concerns quinazoline derivatives of the Formula I: (A chemical formula should be inserted here—please see paper copy enclosed herewith) wherein each of R1, R2, W, X1, X2, Z, a and b are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula I are expected to be useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.

  本发明涉及公式I的喹嗪衍生物：(此处应插入一种化学式，请参见随附的纸质副本)，其中R1、R2、W、X1、X2、Z、a和b的定义如描述中所定义；其制备方法；包含它们的药物组合物以及它们在制造提供抗增殖效果的药物方面的应用。公式I的喹嗪衍生物预计可用于治疗由erbB受体酪氨酸激酶介导的某些癌症，特别是EGFR酪氨酸激酶。
• WATER-MEDIATED CONTROL OF DEPOLYMERIZATION STEP OF GLATIRAMER ACETATE SYNTHESIS
  申请人：Coleman Claire

  公开号：US20110269690A1

  公开（公告）日：2011-11-03

  Methods of making copolymers are described.
• MODULATIONS OF PROTEASE ACTIVATED RECEPTORS
  申请人：Fairlie David Paul

  公开号：US20130184226A1

  公开（公告）日：2013-07-18

  The present invention provides novel compounds of the Formula (1), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.
• MODULATORS OF PROTEASE ACTIVATED RECEPTORS
  申请人：Fairlie David

  公开号：US20140315796A1

  公开（公告）日：2014-10-23

  The present invention provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for therapies such as metabolic syndrome, obesity, type II diabetes, fibrosis and cardiovascular diseases, whether they are used alone or in combination with other treatment modalities.